Spesana, a personalised medicine technology company, and Imidex have partnered to transform early lung cancer detection and patient outcomes.
In a joint clinical study, Imidex and Spesana will integrate their technologies to evaluate the impact of artificial intelligence (AI) on enhancing the detection of lung nodules and masses.
IMIDEX develops AI-based solutions for lung cancer. The company has developed VisiRad XR, a computer-aided detection technology.
In August last year, the technology received the US Food and Drug Administration (FDA) 510(k) clearance to identify lung nodules and masses in chest X-rays.
Under the partnership, VisiRad XR will be integrated into Spesana’s advanced medical data and clinical workflow platform.
The collaborative study is intended to determine the additional number of lung nodules and masses that can be detected in routine chest X-rays.
The data generated will enable both partners to quantify downstream lung cancer detection rates, identify patients suitable for clinical trials through screening, and explore the potential of liquid biopsies.
Imidex CEO Wes Bolsen said: “Imidex is deploying our leading FDA 510(k) cleared algorithm for lung nodule and mass detection to improve the screening of potential future lung cancer patients.
“Our collaboration with Spesana will equip healthcare providers and pharmaceutical companies with the tools they need to identify lung nodules earlier, improve patient outcomes, and optimise healthcare resources.”
VisiRad XR employs advanced computer vision technology to offer 83% sensitivity in detecting lung nodules and masses, often missed during initial assessments.
The collaboration will expand the detection technology accessibility among a wider range of healthcare providers and patients.
Spesana’s platform is engineered to expedite patient referrals to appropriate specialists through a unified medical record system.
It enhances clinical workflows by facilitating real-time collaboration and decision-making support, using insights from real-world data and molecular diagnostics.
Spesana’s Authorize product streamlines the prior authorisation process, reducing delays and accelerating access to optimal care.
By integrating VisiRad XR’s AI capabilities, the medicine technology company aims to equip healthcare providers with patient information, intelligent diagnostic order management, and digital results.
Spesana CEO Carla Balch said: “Our partnership now extends the comprehensive nature of precision medicine by adding imaging diagnostics to our deep existing molecular diagnostic capabilities.”
